The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

The three price benefit managers jointly administer 80% of all prescriptions in the U.S., the FTC said in the lawsuit.

For millions of Americans who rely on insulin to manage their diabetes, the price surge can pose a financial burden.The ...

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...

The global insulin pens market is experiencing rapid expansion, driven by the rising global prevalence of diabetes. According ...

Key drivers include technological advancements and evolving healthcare policies. The global market for short-acting insulin ...

A recent study published in JAMA Network Open reveals that the actual production cost of insulin is ... while its Xultphy 100/3.6 pen, a mixture of insulin glargine and lixisenatide used in the ...

30 and highlighting rail safety legislation and proposals to lower the cost of insulin and prescription drugs as top priorities remaining in 2024. Schumer also said he would make it a priority to ...

The World Health Organization issued a warning last year about insulin pens relabeled and repackaged to look like Ozempic.

Diabetes affects your body’s ability to produce or use insulin, a hormone that allows your body to turn glucose (sugar) into energy. Below are the symptoms that may occur in your body when ...